Education
About Us
Working with TipRanks
Follow Us
Eris Lifesciences Ltd (IN:ERIS)
:ERIS
ERIS Stock Chart & Stats
₹1530.85
₹7.70(0.59%)
At close: 4:00 PM EST
₹1530.85
₹7.70(0.59%)
Day’s Range― - ―
52-Week Range₹1,140.00 - ₹1,909.55
Previous CloseN/A
Volume91.31K
Average Volume (3M)2.07K
Market Cap
₹192.70B
Enterprise Value₹215.99B
Total Cash (Recent Filing)₹2.05B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)44.6
Beta0.64
Next Earnings
May 26, 2026EPS Estimate
11.7Next Dividend Ex-DateN/A
Dividend Yield0.47%
Share Statistics
EPS (TTM)7.30
Shares Outstanding136,216,890
10 Day Avg. Volume1,915
30 Day Avg. Volume2,071
Financial Highlights & Ratios
PEG Ratio-5.23
Price to Book (P/B)6.64
Price to Sales (P/S)6.58
P/FCF Ratio20.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent ~20% revenue growth and a noted 'significant jump' between 2024–2025 indicate durable demand for Eris's branded chronic-therapy portfolio. Recurring prescriptions in diabetes and cardiovascular segments create sticky revenues, supporting predictable medium-term top-line expansion and scale benefits for sales and distribution.
Robust ProfitabilityStrong gross, EBIT and EBITDA margins reflect efficient cost structure and disciplined commercial spending. Sustained margin profiles support internal cash generation, fund brand-building and R&D, and provide resilience to pricing or input-cost shifts, enhancing long-term operational sustainability versus lower-margin peers.
Healthy Balance SheetA solid equity base, manageable leverage and strong ROE give Eris financial flexibility to fund marketing, targeted acquisitions or capex without heavy refinancing. Conservative balance-sheet metrics reduce solvency risk, enabling the company to invest in growth initiatives and withstand industry cyclicality over multiple quarters.
Bears Say
Free Cash Flow VolatilityAlthough operating cash flow has grown, fluctuating Free Cash Flow and a noted decrease in cash balances create uncertainty in cash conversion. Persistent FCF volatility can constrain discretionary investment, limit buffer for shocks, and complicate financing of sustained brand investments or return-of-capital decisions over the medium term.
Concentration In Domestic Branded PrescriptionsRevenue reliance on branded prescription sales in India concentrates market, regulatory and prescriber risks. Changes in pricing policy, reimbursement, or physician prescribing behavior could materially affect volumes and growth. Geographic and channel concentration limits revenue diversification and heightens exposure to domestic healthcare policy shifts.
Manufacturing Mix RiskDependence on a hybrid in-house and contract manufacturing model introduces supply, quality and cost risks. Third‑party reliance can create capacity constraints, margin pressure from vendor cost changes, or quality control issues that disrupt availability of key chronic therapy brands and impede consistent growth execution over time.
Eris Lifesciences Ltd News
ERIS FAQ
What was Eris Lifesciences Ltd’s price range in the past 12 months?
Eris Lifesciences Ltd lowest stock price was ₹1140.00 and its highest was ₹1909.55 in the past 12 months.
What is Eris Lifesciences Ltd’s market cap?
Eris Lifesciences Ltd’s market cap is ₹192.70B.
When is Eris Lifesciences Ltd’s upcoming earnings report date?
Eris Lifesciences Ltd’s upcoming earnings report date is May 26, 2026 which is in 99 days.
How were Eris Lifesciences Ltd’s earnings last quarter?
Eris Lifesciences Ltd released its earnings results on Feb 13, 2026. The company reported ₹7.3 earnings per share for the quarter, missing the consensus estimate of ₹9.625 by -₹2.325.
Is Eris Lifesciences Ltd overvalued?
According to Wall Street analysts Eris Lifesciences Ltd’s price is currently Overvalued.
Does Eris Lifesciences Ltd pay dividends?
Eris Lifesciences Ltd pays a Annually dividend of ₹7.35 which represents an annual dividend yield of 0.47%. See more information on Eris Lifesciences Ltd dividends here
What is Eris Lifesciences Ltd’s EPS estimate?
Eris Lifesciences Ltd’s EPS estimate is 11.7.
How many shares outstanding does Eris Lifesciences Ltd have?
Eris Lifesciences Ltd has 136,216,890 shares outstanding.
What happened to Eris Lifesciences Ltd’s price movement after its last earnings report?
Eris Lifesciences Ltd reported an EPS of ₹7.3 in its last earnings report, missing expectations of ₹9.625. Following the earnings report the stock price went down -6.38%.
Which hedge fund is a major shareholder of Eris Lifesciences Ltd?
Currently, no hedge funds are holding shares in IN:ERIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eris Lifesciences Ltd
Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.
Technical Analysis
Emcure Pharmaceuticals Limited
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
Sanofi Consumer Healthcare India Limited
―